Abstract
Acute myeloid leukemia (AML) is a common malignant heterogeneous hematopoietic disease with a very low average 5-year survival rate due to its refractory nature and high rate of relapse. CD123 is highly expressed on multiple types of AML cells, especially leukemia stem cells, and is closely associated with poor prognosis. Aiming to meet the urgent demand for targeted therapeutics for refractory AML patients, researchers synthesized a CD123 antagonistic peptide (PO-6) loaded in nanomicelles (<sup>m</sup>PO-6). This study investigated its therapeutic effect and pharmacokinetics on a lab-established refractory AML mice model (AE & CKIT<sup>D816V</sup>). Results show that PO-6 effectively binds to CD123<sup>+</sup> AML cells, and the micellar formulation <sup>m</sup>PO-6 increases dissolution stability and specific binding capacity. When injected intravenously, <sup>m</sup>PO-6 significantly prolongs the survival of refractory AML mice by interfering with the CD123/IL-3 axis, evidenced by the downregulation of STAT5 and PI3K/AKT phosphorylation and the inhibition of activated NF-κB. This antagonistic effect leads to a significant reduction of AML cell infiltration in the bone marrow, suggesting <sup>m</sup>PO-6 as a potent targeted treatment for AML.
Introduction: The Challenge of Refractory AML
Acute Myeloid Leukemia (AML) remains a clinical "hard nut to crack," with a 5-year survival rate of only around 25%. The primary culprits are refractory disease—cancer that doesn't respond to treatment—and high relapse rates, often driven by leukemia stem cells.
The protein CD123 (the alpha chain of the IL-3 receptor) is a prime target because it is found on roughly 80% of AML cells and stem cells but is largely absent from healthy blood-forming cells. While previous attempts using anti-CD123 antibodies have seen underwhelming clinical results, peptides offer a smaller, more agile alternative. However, peptides usually suffer from poor stability and short half-lives in the bloodstream. This research bridges that gap by combining a de novo designed peptide with a protective micellar delivery system.
Innovative Design: Peptide Engineering and Micellar Delivery
To address the stability issues common with peptides, the researchers loaded the CD123-binding peptide PO-6 into amphiphilic polymeric micelles. These self-assembling nanocarriers (averaging 38 nm in diameter) protect the peptide and improve its binding capacity.
The micellar formulation (<sup>m</sup>PO-6) performed better than the "naked" peptide. The micelles improved the peptide's dissolution stability in physiological conditions, leading to a more homogenous distribution on the cell membrane and higher binding amounts, as confirmed by flow cytometry.
Mechanism of Action: Disrupting the CD123/IL-3 Axis
The drug works by physically blocking the "CD123/IL-3 axis." By preventing IL-3 from binding to its receptor, the drug shuts down downstream survival signals like STAT5, PI3K/AKT, and NF-κB.
RNA-sequencing (RNA-seq) revealed that <sup>m</sup>PO-6 treatment significantly altered the transcriptomic profile of AML cells, down-regulating 1,716 genes and up-regulating 1,556 others. Specifically, it suppressed genes related to inflammation and survival (TNF, RIG-I-like receptors) while boosting pathways related to p53 and apoptosis (programmed cell death).
Therapeutic Efficacy and Safety
The most significant finding was the drug's efficacy in a model specifically resistant to standard chemotherapy (cytarabine). In the refractory AML mouse model, <sup>m</sup>PO-6 significantly prolonged median survival compared to control groups, extending life by approximately 25-30% in the tested window. Histological analysis of bone marrow showed a marked reduction in leukemia cell infiltration.
Importantly, the treatment showed a favorable safety profile. At a dose of 10 mg/kg, the treatment showed no significant toxicity to white blood cells, red blood cells, or platelets in healthy mice, and the peptide was safely excreted through the kidneys.
Conclusion and Future Directions
In conclusion, <sup>m</sup>PO-6 provides a potent antagonistic therapeutic approach for the targeted treatment of AML. While the results in mice and primary patient blasts are encouraging, future work will need to address long-term organ accumulation and explore potential synergistic effects when combined with low-dose chemotherapy to achieve total remission in human patients.
Summary updated